Nov 18

PharmaShots: Enhancing Care with NK Cell Therapy

Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots discusses:

  • Immune reset in oncology has been observed with approved autologous CAR-T products. A study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases
  • Artiva’s AlloNK, an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate. AlloNK is designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies (mAbs) to drive B-cell depletion
  • The funding raised through Artiva’s IPO, ongoing clinical trials, and the therapeutic strategy utilizing NK cells to advance oncology and autoimmune therapies.

Read the full interview here.

Recent Posts

See All

SDBJ: Artiva Raises $300M to Fund Phase 3 Trial for RA Cell Therapy

Artiva was featured in San Diego Business Journal following its $300 million financing to support the continued advancement of AlloNK® in autoimmune disease. The article discusses the company’s planned Phase 3 trial in refractory rheumatoid arthritis and its focus on developing an outpatient-ready, scalable approach to deep B-cell depletion. Read the article here (subscription may...

Biotech2050 Podcast: Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Over the past decade, CAR-T therapies have demonstrated curative potential, while also underscoring how complexity, cost, and infrastructure can limit the number of patients who can be treated. In this episode of the Biotech2050 podcast, Artiva’s CEO Fred Aslan discusses how lessons from the first generation of CAR-T therapies are shaping new approaches in autoimmune...

Base to Base Biotech Podcast: Natural Killer Cell Therapy

In rheumatoid arthritis, existing therapies frequently fall short of delivering sustained disease control, despite sequential use of biologic and targeted agents. In a this episode of the 𝗕𝗮𝘀𝗲 𝘁𝗼 𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁, Lisa Guerrettaz, Executive Director, Pharmacology and Translational Science at Artiva Biotherapeutics, discusses how the limitations of currently approved treatments are driving the development...

Secret Link